Navigation Links
Cellu Tissue Holdings, Inc. Files Registration Statement for Proposed Initial Public Offering of Common Stock
Date:10/16/2009

ALPHARETTA, Ga., Oct. 16 /PRNewswire/ -- Cellu Tissue Holdings, Inc. ("Cellu Tissue") today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the "SEC") relating to a proposed initial public offering of shares of its common stock. The offered shares will include shares to be sold by Cellu Tissue and shares to be sold by stockholders of the company. The total number of shares to be offered, the allocation of shares to be sold as between Cellu Tissue and stockholders and the price range for the offering have not yet been determined. Cellu Tissue intends to use the net proceeds it receives from the offering to pay down certain indebtedness, including, but not limited to, potentially redeeming or repurchasing a portion of its outstanding senior secured notes, and the remaining net proceeds, if any, for general corporate purposes. Cellu Tissue will not receive any of the proceeds from the sale of shares by the selling stockholders.

Cellu Tissue intends to apply to list the common stock on the New York Stock Exchange under the ticker symbol "CLU."

Goldman, Sachs & Co. and J.P. Morgan Securities Inc. will act as joint book running managers for the offering. The offering will only be made by means of a prospectus. A copy of the preliminary prospectus, when available, may be obtained by contacting either Goldman, Sachs & Co., at 85 Broad Street, New York, NY 10004, Attention: Prospectus Department, by telephone at 1-866-471-2526 or by emailing Prospectus-ny@ny.email.gs.com, or J.P. Morgan Securities Inc. at National Statement Processing, Prospectus Library, 4 Chase Metrotech Center, CS Level, Brooklyn, New York, NY, 11245, or by telephone at 718-242-8002.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which the offer, solicitation or sale of securities would be unlawful prior to their registration and qualification under the securities laws of any such state or jurisdiction.

SOURCE Cellu Tissue Holdings, Inc.


'/>"/>
SOURCE Cellu Tissue Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
2. Cellumen Establishes Collaboration in Breast Cancer Patient Stratification
3. Genencor Launches First Ever Commercial Enzyme Product for Cellulosic Ethanol
4. EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference
5. National Stem Cell Holding Announces Patent Application for Newly Discovered Cellular Derived Biomaterials for Anti-Aging Applications
6. Aton Pharma Introduces Expanded Distribution of Lacrisert(R) (hydroxypropyl cellulose ophthalmic insert) at Hawaiian Eye
7. Chris Tihansky Appointed President of In Vivo Cellular Imaging Leader Cellvizio Inc.
8. Enerkem announces progress on construction of Canadas first cellulosic ethanol plant
9. First Live U.S. Demonstration of Cellvizio GI In Vivo Cellular Imaging Technology to Occur at Johns Hopkins Conference
10. Cellular construction methods emulated
11. GreenField Ethanol and Enerkem Announce Plans to Make Cellulosic Ethanol a Commercial Reality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Dec. 8, 2016  Soligenix, Inc. (OTCQB: SNGX) ... focused on developing and commercializing products to treat ... need, announced today the long-term follow-up data from ... a first-in-class Innate Defense Regulator (IDR), in the ... neck cancer patients undergoing chemoradiation therapy (CRT).  The ...
(Date:12/8/2016)... 2016 Savannah River Remediation LLC group ... NewTechBio,s NT-MAX Lake & Pond Sludge and ... in conjunction with Hexa Armor/ Rhombo cover manufactured ... Pollutant Discharge Elimination System requirements. The ... history of elevated pH levels, above 8.5, especially ...
(Date:12/8/2016)... , Dec. 8, 2016   Biocept, Inc ... commercial provider of clinically actionable liquid biopsy tests ... that clinical data featuring its Target Selector™ Circulating ... biopsy for the detection of actionable biomarkers in ... research sponsored by Sara Cannon Research Institute (SCRI), ...
(Date:12/7/2016)... ... December 07, 2016 , ... Huffman Engineering, ... become a Wonderware Certified System Integrator Partner. Huffman Engineering is the only ... , “The System Integrator Partner certification gives customers confidence that our engineers are ...
Breaking Biology Technology:
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is to ... for Private Biobanks shows the highest Compounded Annual Growth Rate ... region during the analysis period 2014-2020. North ... of 9.95% followed by Europe at ...
(Date:11/16/2016)... , Nov. 16, 2016 Sensory ... experience and security for consumer electronics, and ... financial and retail industry, today announced a global ... convenient way to authenticate users of mobile banking ... TrulySecure™ software which requires no specialized ...
(Date:11/15/2016)... Research and Markets has announced the addition of the "Bioinformatics ... ... The global bioinformatics market is projected ... in 2016, growing at a CAGR of 21.1% during the forecast ... by the growing demand for nucleic acid and protein sequencing, increasing ...
Breaking Biology News(10 mins):